GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.

King AC, Wellendorf C, Atkinson EA, de Carvalho MEA, Fridberg DJ, Pannain S

Journal of addiction medicine12 Aug 2025Cited by 1 (Europe PMC)

PMID40792626DOI10.1097/adm.0000000000001565PepBankPUB-40792626

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including liraglutide, BMI decreased over time.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including liraglutide was linked to lower BMI over time.
Peptide
Liraglutide
Outcome
DecreaseBMI
Study
n = 14
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
2 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4079262601
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including semaglutide, BMI decreased over time.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including semaglutide was linked to lower BMI over time.
Peptide
Semaglutide
Outcome
DecreaseBMI
Study
n = 14
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
2 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4079262602
03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including tirzepatide, BMI decreased over time.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including tirzepatide was linked to lower BMI over time.
Peptide
Tirzepatide
Outcome
DecreaseBMI
Study
n = 14
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
2 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4079262603
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including liraglutide, hazardous drinking scores declined significantly over time, with large effect sizes reported.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including liraglutide was linked to lower hazardous-drinking scores.
Peptide
Liraglutide
Outcome
DecreaseHazardous drinking score
Study
n = 14
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
5 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes were large, indicating a high magnitude of the effect of GLP-1 RA medications on reducing hazardous drinking scores.
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4079262604
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including semaglutide, hazardous drinking scores declined significantly over time, with large effect sizes reported.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including semaglutide was linked to lower hazardous-drinking scores.
Peptide
Semaglutide
Outcome
DecreaseHazardous drinking score
Study
n = 14
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
5 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes were large, indicating a high magnitude of the effect of GLP-1 RA medications on reducing hazardous drinking scores.
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4079262605
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients prescribed pooled GLP-1 receptor agonist therapy including tirzepatide, hazardous drinking scores declined significantly over time, with large effect sizes reported.
In plain wordsIn patients with hazardous drinking and overweight or obesity, pooled GLP-1 treatment including tirzepatide was linked to lower hazardous-drinking scores.
Peptide
Tirzepatide
Outcome
DecreaseHazardous drinking score
Study
n = 14
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
5 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes were large, indicating a high magnitude of the effect of GLP-1 RA medications on reducing hazardous drinking scores.
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4079262606
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
Among patients prescribed pooled GLP-1 receptor agonist therapy including liraglutide, the very high AUDIT group had more pronounced score reductions than the high AUDIT group.
In plain wordsAmong patients with overweight or obesity, initially very-high versus high AUDIT groups showed larger reductions during pooled GLP-1 treatment including liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHazardous drinking score reduction by baseline severity
Study
n: not reported in source
Comparator
High AUDIT group
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
4 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4079262607
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Among patients prescribed pooled GLP-1 receptor agonist therapy including semaglutide, the very high AUDIT group had more pronounced score reductions than the high AUDIT group.
In plain wordsAmong patients with overweight or obesity, initially very-high versus high AUDIT groups showed larger reductions during pooled GLP-1 treatment including semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHazardous drinking score reduction by baseline severity
Study
n: not reported in source
Comparator
High AUDIT group
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
4 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4079262608
09HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among patients prescribed pooled GLP-1 receptor agonist therapy including tirzepatide, the very high AUDIT group had more pronounced score reductions than the high AUDIT group.
In plain wordsAmong patients with overweight or obesity, initially very-high versus high AUDIT groups showed larger reductions during pooled GLP-1 treatment including tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseHazardous drinking score reduction by baseline severity
Study
n: not reported in source
Comparator
High AUDIT group
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
There were significant reductions in BMI and AUDIT scores over time, with patients in the very high AUDIT group reporting more pronounced reductions in AUDIT scores compared with those in the high AUDIT group.
4 context sentences(design, population, supporting numbers)
Summary · context
The present prospective observational study investigated hazardous alcohol drinking in patients at the University of Chicago Weight Loss Clinic.
Summary · context
Fourteen patients were prescribed a GLP-1 RA for overweight or obesity (liraglutide [n=1], semaglutide [n=8], and tirzepatide [n=5]), along with standard care dietary counseling and physical activity recommendations.
Summary · context
Patients screened positive for hazardous drinking on the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and were categorized into subgroups of high (score 8-14) and very high AUDIT (score ≥15).
Summary · context
The AUDIT was readministered on average 9.6 (±4.8) months after medication initiation.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4079262609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.